Copy link
Export CSV
Cite this view
HANK Price Transparency. (n.d.).
tremelimumab-actl 20 mg/mL Inj Soln 15mL (Imjudo) (OTHER 6704760) by State .
PPMan price-transparency data, derived from CMS-required hospital MRFs.
Retrieved July 1, 2026 , from http://ppman.hank.ai/transparency/procedure/6704760/by-state?code_type=OTHER
“tremelimumab-actl 20 mg/mL Inj Soln 15mL (Imjudo) (OTHER 6704760) by State.” HANK Price Transparency ,
http://ppman.hank.ai/transparency/procedure/6704760/by-state?code_type=OTHER. Accessed
July 1, 2026 .
“tremelimumab-actl 20 mg/mL Inj Soln 15mL (Imjudo) (OTHER 6704760) by State,” HANK Price Transparency ,
accessed July 1, 2026 ,
http://ppman.hank.ai/transparency/procedure/6704760/by-state?code_type=OTHER.
Source: PPMan price-transparency data, derived from CMS-required hospital
machine-readable files (45 CFR 180). See
methodology .
Print / Save PDF
OTHER · across United States
6704760 — Tremelimumab-actl 20 mg/mL Inj Soln 15mL (Imjudo)
State-by-state median negotiated rates. Lower bars are cheaper states; the
range bar shows the IQR (25th to 75th percentile within each state).
$124,922
National median
$113,896 – $125,450
IQR (p25 – p75)
1
hospitals filing
1
states
Median negotiated rate, by state
Ranked by typical (median) negotiated price. Hover for state-level IQR.
Median negotiated rate by state for 6704760 (OTHER), with interquartile range
State Median p25 p75
WV $124,922 $113,896 $125,450